Huitao Wang1, Kewei Fang1, Jinsong Zhang1, Yongming Jiang1, Guang Wang1, Haiyan Zhang1, Tao Chen1, Xin Shi1, Yuhang Li1, Fei Duan1, Jianhe Liu2. 1. Department of Urology, The Second Affiliated Hospital of Kunming Medical University, No. 374, Dianmian Dadao Road, Kunming, 650101, Yunnan, People's Republic of China. 2. Department of Urology, The Second Affiliated Hospital of Kunming Medical University, No. 374, Dianmian Dadao Road, Kunming, 650101, Yunnan, People's Republic of China. clinurology@cntv.cn.
Abstract
PURPOSE: To illustrate whether De Ritis (aspartate transaminase-AST/alanine transaminase-ALT) ratio is useful in risk stratification of localized prostate cancer and propose an easy predictive model for biochemical recurrence-free survival (BCRFS). METHODS: In total, 438 patients who underwent radical prostatectomy were included in this study. Blood samples including AST and ALT were collected 1-7 days before surgery. An elevated AST and ALT value was defined as over 40 or 56 IU/L. RESULTS: The median AST and ALT value was 18.5 (16-22) and 14 (11-18) IU/L. In total, 15 patients (3.4%) and 9 patients (2.1%) exhibited elevated AST value and ALT value. The median De Ritis ratio was 1.33 (1.11-1.60), and ROC curve indicated the best cutoff of 1.325 in predicting the occurrence of biochemical recurrence. Higher De Ritis ratio was found to be related to older age (p < 0.001), higher tumor stages (p < 0.001) and Gleason Score (p < 0.001), presence of seminal invasion (p < 0.001), positive surgical margin (p < 0.001) and lymph node metastasis (p = 0.003). Multivariate logistic regression confirmed that De Ritis ratio was an independent predictor for final Gleason Score (p < 0.001), and multivariate Cox regression demonstrated De Ritis ratio as an independent risk factor for BCRFS. A simple predictive model which incorporated De Ritis ratio, pathological tumor stage and final Gleason Score could help risk stratification for BCRFS. CONCLUSION: Higher De Ritis ratio could be predictive for worse pathological outcomes and higher BCR in localized prostate cancer patients. A predictive model which incorporates De Ritis ratio, Gleason Score and pathological tumor stage could help risk stratification for BCRFS.
PURPOSE: To illustrate whether De Ritis (aspartate transaminase-AST/alanine transaminase-ALT) ratio is useful in risk stratification of localized prostate cancer and propose an easy predictive model for biochemical recurrence-free survival (BCRFS). METHODS: In total, 438 patients who underwent radical prostatectomy were included in this study. Blood samples including AST and ALT were collected 1-7 days before surgery. An elevated AST and ALT value was defined as over 40 or 56 IU/L. RESULTS: The median AST and ALT value was 18.5 (16-22) and 14 (11-18) IU/L. In total, 15 patients (3.4%) and 9 patients (2.1%) exhibited elevated AST value and ALT value. The median De Ritis ratio was 1.33 (1.11-1.60), and ROC curve indicated the best cutoff of 1.325 in predicting the occurrence of biochemical recurrence. Higher De Ritis ratio was found to be related to older age (p < 0.001), higher tumor stages (p < 0.001) and Gleason Score (p < 0.001), presence of seminal invasion (p < 0.001), positive surgical margin (p < 0.001) and lymph node metastasis (p = 0.003). Multivariate logistic regression confirmed that De Ritis ratio was an independent predictor for final Gleason Score (p < 0.001), and multivariate Cox regression demonstrated De Ritis ratio as an independent risk factor for BCRFS. A simple predictive model which incorporated De Ritis ratio, pathological tumor stage and final Gleason Score could help risk stratification for BCRFS. CONCLUSION: Higher De Ritis ratio could be predictive for worse pathological outcomes and higher BCR in localized prostate cancerpatients. A predictive model which incorporates De Ritis ratio, Gleason Score and pathological tumor stage could help risk stratification for BCRFS.
Authors: Axel Heidenreich; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Nicolas Mottet; Hans-Peter Schmid; Theo van der Kwast; Thomas Wiegel; Filliberto Zattoni Journal: Eur Urol Date: 2010-10-28 Impact factor: 20.096
Authors: Angelika Bezan; Edvin Mrsic; Daniel Krieger; Tatjana Stojakovic; Karl Pummer; Richard Zigeuner; Georg C Hutterer; Martin Pichler Journal: J Urol Date: 2015-01-23 Impact factor: 7.450
Authors: Björn Glinghammar; Ingalill Rafter; Anna-Karin Lindström; Jesper J Hedberg; Håkan B Andersson; Per Lindblom; Anna-Lena Berg; Ian Cotgreave Journal: Int J Mol Med Date: 2009-05 Impact factor: 4.101
Authors: Jakob Michael Riedl; Florian Posch; Gerald Prager; Wolfgang Eisterer; Leopold Oehler; Thamer Sliwa; Klaus Wilthoner; Andreas Petzer; Petra Pichler; Eva Hubmann; Thomas Winder; Sonja Burgstaller; Markus Korger; Johannes Andel; Richard Greil; Hans-Joerg Neumann; Martin Pecherstorfer; Kathrin Philipp-Abbrederis; Angela Djanani; Birgit Gruenberger; Friedrich Laengle; Ewald Wöll; Armin Gerger Journal: Ther Adv Med Oncol Date: 2020-04-10 Impact factor: 8.168
Authors: Fahad Quhal; Mohammad Abufaraj; Florian Janisch; Keiichiro Mori; Ivan Lysenko; Hadi Mostafaei; David D'Andrea; Romain Mathieu; Dmitry V Enikeev; Harun Fajkovic; Axel Heidenreich; Shahrokh F Shariat Journal: Arab J Urol Date: 2020-05-31
Authors: Markus Galler; Julian M M Rogasch; Kai Huang; Henning Jann; Kristina Plehm; Christoph Wetz; Holger Amthauer Journal: Cancers (Basel) Date: 2022-03-31 Impact factor: 6.639